Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

AVTX

Avalo Therapeutics (AVTX)

Avalo Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AVTX
FechaHoraFuenteTítuloSímboloCompañía
24/02/202506:00GlobeNewswire Inc.Avalo Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
04/02/202507:00GlobeNewswire Inc.Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceNASDAQ:AVTXAvalo Therapeutics Inc
30/01/202516:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
13/01/202506:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
03/01/202515:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
02/01/202506:00GlobeNewswire Inc.Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy OfficerNASDAQ:AVTXAvalo Therapeutics Inc
31/12/202415:13Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVTXAvalo Therapeutics Inc
14/11/202411:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
12/11/202406:00GlobeNewswire Inc.Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsNASDAQ:AVTXAvalo Therapeutics Inc
11/11/202406:00GlobeNewswire Inc.Avalo Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202406:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202406:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTXAvalo Therapeutics Inc
07/11/202406:00GlobeNewswire Inc.Avalo Reports Third Quarter 2024 Financial Results and Recent Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202406:00GlobeNewswire Inc.Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaNASDAQ:AVTXAvalo Therapeutics Inc
07/10/202419:06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVTXAvalo Therapeutics Inc
04/09/202406:00GlobeNewswire Inc.Avalo Announces Participation in September Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
12/08/202406:00GlobeNewswire Inc.Avalo Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
05/08/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AVTXAvalo Therapeutics Inc
05/08/202415:36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AVTXAvalo Therapeutics Inc
29/07/202415:08Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
16/07/202406:00GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerNASDAQ:AVTXAvalo Therapeutics Inc
11/07/202415:12Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
24/06/202415:01GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerNASDAQ:AVTXAvalo Therapeutics Inc
17/06/202406:30GlobeNewswire Inc.Avalo to Present at the Oppenheimer Novel Targets in Immunology SummitNASDAQ:AVTXAvalo Therapeutics Inc
07/06/202406:01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
06/06/202415:03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AVTXAvalo Therapeutics Inc
03/06/202406:20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
13/05/202411:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVTXAvalo Therapeutics Inc
13/05/202406:30GlobeNewswire Inc.Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
02/04/202406:00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:AVTXAvalo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AVTX

Su Consulta Reciente

Delayed Upgrade Clock